U.S. Pays $200k to Study Impact of Stigma, Minority Stress on “Gender Nonconforming People”

Share:

The Trump administration is spending hundreds of thousands of dollars to conduct research on transgender health, including “gender nonconforming people of all ages,’ according to a U.S. government grant announcement. The money will flow through the National Institutes of Health (NIH), the nation’s medical research agency and will focus on both youth and adults who are questioning their gender identity as well as individuals who are making or who have made a transition from being identified as one gender to the other. “This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex,” the government document states.

The taxpayer dollars will fund “exploratory or developmental research” on the health of transgender and gender nonconforming people and will address the medical, sociological, psychological and structural causes and consequences of transgender and gender nonconforming identities. “Investigations of the social determinants of health in these populations are needed, including understanding the impact of stigma, the high impact of HIV, minority stress, education, employment, violence, homelessness, and incarceration,” the government announcement says. “More information is needed on relationships with partners and family, as well as on sexual and reproductive health. Successful aging, including the impact of life events, experiences, and interventions such as hormone therapy and surgery are other important topics to investigate. It will also be important to learn more about brain development, resilience, and end-of-life issues.”

READ MORE

[contentcards url=”http://www.judicialwatch.org/blog/2017/09/u-s-pays-200k-study-impact-stigma-minority-stress-gender-nonconforming-people/” target=”_blank”]
Share:
No Comments Yet

Leave a Reply

2021 © True Pundit. All rights reserved.